Shopping Cart
- Remove All
![TargetMol](https://newstatic.targetmol.com/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $43 | In Stock | |
5 mg | $98 | In Stock | |
10 mg | $163 | In Stock | |
25 mg | $297 | In Stock | |
50 mg | $497 | In Stock | |
100 mg | $693 | In Stock | |
200 mg | $982 | In Stock | |
500 mg | $1,450 | In Stock | |
1 mL x 10 mM (in DMSO) | $123 | In Stock |
Description | SLC13A5-IN-1 is a selective inhibitor of sodium-citrate co-transporter (SLC13A5),completely blocks the uptake of 14C-citrate(IC50 : 0.022 μM in HepG2 cells). |
In vitro | In HepG2/14C-Citrate Uptake Assay,SLC13A5-IN-1 exhibits an IC50 of 0.022 μM . HepG2 cells endogenously express hSLC13A5 transporter which is responsible for the uptake of citrate into these cells. Uptake of 14C-citrate can be completely blocked by SLC13A5-IN-1 and the signal can be competed with unlabelled citrate.In recombinant hSLC3A5/14C-Citrate Uptake Assay, SLC13A5-IN-1 exhibits an IC50 of 0.056 μM . SLC13A5-IN-1 exhibits an IC50 of 100 μM in recombinant Human GlyT2/3H-Glycine Uptake Assay. The human embryonic kidney 293 cells are used that stably over-express the human GlyT2 receptor which is responsible for the uptake of glycine into these cells. Uptake of 3H-glycine can be completely blocked by SLC13A5-IN-1. |
Molecular Weight | 461.79 |
Formula | C19H19Cl3N2O3S |
Cas No. | 2227548-95-8 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | ||||||||||||||||||||
Solubility Information | DMSO: 5 mg/ml (10.83 mM) ![]() | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.